FY2025 EPS Estimates for Zura Bio Boosted by HC Wainwright

Zura Bio Limited (NASDAQ:ZURA) – Stock analysts at HC Wainwright raised their FY2025 earnings per share estimates for Zura Bio in a report released on Tuesday, August 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.74) per share for the year, up from their previous estimate of ($0.76). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02.

Other equities analysts have also issued reports about the company. Oppenheimer decreased their price objective on Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, August 15th. Chardan Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Zura Bio in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $14.00.

Zura Bio Price Performance

Shares of ZURA stock opened at $1.75 on Thursday. Zura Bio has a 12-month low of $0.97 and a 12-month high of $5.07. The firm has a market capitalization of $119.67 million, a price-to-earnings ratio of -2.50 and a beta of -0.06. The business has a 50 day simple moving average of $1.40 and a 200 day simple moving average of $1.32.

Hedge Funds Weigh In On Zura Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Advisers LP bought a new position in Zura Bio during the 4th quarter valued at $32,000. ProShare Advisors LLC bought a new position in Zura Bio during the 4th quarter valued at $35,000. XTX Topco Ltd bought a new position in Zura Bio during the 4th quarter valued at $44,000. Wells Fargo & Company MN boosted its stake in Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock valued at $58,000 after purchasing an additional 9,379 shares in the last quarter. Finally, Jump Financial LLC bought a new position in Zura Bio during the 4th quarter valued at $59,000. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.